How to buy Pro Medicus (PME) shares

Learn how to easily invest in Pro Medicus shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Pro Medicus is a health information services business based in Australia. Pro Medicus shares (PME) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollar. Pro Medicus has a trailing 12-month revenue of around $67.9 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Pro Medicus

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Pro Medicus. Find the share by name or ticker symbol: PME. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pro Medicus reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check on your investment. Congratulations, you own a part of Pro Medicus. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

Pro Medicus stock price (ASX:PME)

Use our graph to track the performance of PME stocks over time.

Pro Medicus shares at a glance

Information last updated 2022-01-22.
52-week range$37.8906 - $69.9044
50-day moving average $57.5504
200-day moving average $54.93
Target price$57.9
PE ratio 153.8305
Dividend yield $0.15 (0.35%)
Earnings per share (TTM) $0.295

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
ThinkMarkets Share Trading
AUD $8
ASX shares
$8 flat fee brokerage for CHESS Sponsored ASX stocks (HIN ownership), plus free live stock price data on an easy to use mobile app.
Superhero share trading
ASX shares, US shares, ETFs
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
GO Markets Share Trading
ASX shares, Forex, CFDs, ETFs
Pay zero brokerage on your first 20 trades and $7.70 after that on over 2,500 ASX listed shares from either your desktop or mobile.
Opentrader Share Trading
AUD $5
ASX shares, Options trading, ETFs, Warrants
Gain access to chess sponsored shares for as little as $5 per trade.
Get free live data, advanced charting and even gain experience before trading through fantasy portfolios when you sign up with OpenTrader.
Saxo Capital Markets (Classic account)
AUD $5
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
HSBC Online Share Trading
AUD $19.95
ASX shares, mFunds, ETFs, Bonds
Limited-time offer: Join HSBC’s online trading account before 28 February 2022 and HSBC will reimburse you up to $100 on your first 5 trades. Also traders who transfer $50k+ will get a $200 bonus(T&Cs apply).
Make trades online with brokerage fees starting from just $19.95 with an HSBC Online Share Trading account. Plus gain access to complimentary expert research, trading ideas and tools.
SelfWealth (Basic account)
AUD $9.5
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Bell Direct Share Trading
AUD $15
ASX shares, mFunds, ETFs
Invest in Australian shares, options and managed funds from the one account with no inactivity fee.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.

Compare up to 4 providers

Is it a good time to buy Pro Medicus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Pro Medicus price performance over time

Historical closes compared with the last close of A$41.78

1 week (2022-01-21) -7.93%
1 month (2021-12-24) -31.51%
3 months (2021-10-28) -23.55%
6 months (2021-07-28) -25.70%
1 year (2021-01-28) 1.41%
2 years (2020-01-28) 63.46%
3 years (2019-01-25) 230.28%
5 years (2017-01-27) 716.02%

Is Pro Medicus under- or over-valued?

Valuing Pro Medicus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pro Medicus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pro Medicus's P/E ratio

Pro Medicus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 154x. In other words, Pro Medicus shares trade at around 154x recent earnings.

That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pro Medicus's EBITDA

Pro Medicus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $42.6 million (£0.0 million).

The EBITDA is a measure of a Pro Medicus's overall financial performance and is widely used to measure a its profitability.

Pro Medicus financials

Revenue TTM $67.9 million
Operating margin TTM 62.43%
Gross profit TTM $67.4 million
Return on assets TTM 23.95%
Return on equity TTM 43.49%
Profit margin 45.45%
Book value 0.784
Market capitalisation $4.7 billion

TTM: trailing 12 months

Pro Medicus share dividends


Dividend payout ratio: 50% of net profits

Recently Pro Medicus has paid out, on average, around 50% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pro Medicus shareholders could enjoy a 0.35% return on their shares, in the form of dividend payments. In Pro Medicus's case, that would currently equate to about A$0.15 per share.

Pro Medicus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 8 September 2021 (the "ex-dividend date").

Pro Medicus share price volatility

Over the last 12 months, Pro Medicus's shares have ranged in value from as little as $37.8906 up to $69.9044. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Pro Medicus's is 0.2277. This would suggest that Pro Medicus's shares are less volatile than average (for this exchange).

Pro Medicus overview

Pro Medicus Limited develops and supplies healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. It provides Radiology Information Systems (RIS) proprietary medical software for practice management. The company also offers Healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software;, an e-health platform; and integration products. In addition, it offers Visage Ease Pro, a mobile application, which allow users to interpret medical imaging studies that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Pro Medicus in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site